Existing data yield insights into depression among understudied groups

Macarius Donneyong’s research involves digging into existing datasets to find golden nuggets of insight that can improve healthcare outcomes in real-world situations. An assistant professor of pharmacy practice and science in the College of Pharmacy, he recently received an NIH grant to study the treatment of depression among older adults with co-investigator Olivia Ifeoma Okereke, an associate professor at Harvard Medical School and associate psychiatrist at Brigham and Women’s Hospital.

Macarius Donneyong

Macarius Donneyong

“Drugs are approved based on evidence from randomized, controlled trials, but when they are released to market, they are used by a wider population, including people who are underrepresented in the trials,” explains Donneyong. “Most drug trials have an age cut-off of 60 or 65 years,” he says. “We don’t have enough information on the efficacy of these drugs in the general population, and in this age group.”

The dataset itself will be one of the innovations of the research, Donneyong says. He and Okereke will use the database from the Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL, or VITAL-DEP, a large ongoing study directed by Okereke. That study looks at the use of vitamin D and omega-3 fatty acids for the treatment of depression in older adults. Donneyong and Okereke will combine the VITAL-DEP information with Medicare Part D data, including prescription information. The dataset includes demographic information contributed by study participants.

“We are developing this database for the first time, but it will be useful for other studies as well,” says Donneyong. “It’s a challenge, but we have some experience with that. It’s definitely a good way to invest resources, because once created it will be very useful. The two databases complement each other.”

The study is not only diverse in terms of age, but also has greater minority representation; about 25 percent of the individuals represented in the VITAL-DEP database have minority racial or ethnic backgrounds that are often underrepresented in drug trials for a variety of reasons, including institutional stigma, a preference for non-pharmaceutical treatments, and distrust of the medical system.

The study will look at both the effectiveness of depression treatment and participants’ adherence to the treatment plan. “There’s some strong debate within the clinical community, some saying SSRIs don’t work, and others are saying of course they don’t work when people aren’t taking it properly,” said Donneyong.

Donneyong’s previous research has also involved poring over data from clinical practice to understand how people manage their health when they are not among a carefully selected population taking a drug in ideal conditions, but people attempting to manage their health and live their everyday lives as well.

Share this page
Suggested Articles
STEM Profile: With a passion for math, Turkmen not just a statistic at OSU-Newark

Author: Drew Bracken, Correspondent at Newark Advocate Asuman Turkmen, a native of Adana, Turkey, had always maintained an interested in STEM-related fields. After obtaining her Bachelor’s in Mathematics and Master’s...

Why governments have the right to require masks in public

Requirements for consumers to wear masks at public places like retail stores and restaurants are very similar to smoking bans, according to three university experts.  Writing in the American Journal...

Qin finishes fourth in worldwide IARPA challenge

Assistant Professor and TDA affiliate Rongjun Qin (shown at right) placed fourth out of 364 participants worldwide in the Multi-view Stereo 3D Mapping Master Challenge hosted by the Intelligence Advanced Research Projects...

Vuolo awarded Fulbright U.S. Scholar Grant

TDAI affiliate Michael Vuolo, associate professor of sociology, is the recipient of a prestigious 2018-2019 Fulbright-Schuman European Union Affairs Program award, which is designed to strengthen relationships between the U.S....

Study shows the power of how nations follow others in ratifying agreements

By Jeff GrabmeierOhio State News | grabmeier.1@osu.edu New research shows just how powerful the United States’ and other countries’ influence can be on persuading other nations to ratify international treaties. The...